A population-based controlled study to determine whether adult (55-74 years) neurological disease deaths are continuing to rise and are there significant differences between America and the twenty developed countries 1989-91 and 2012-14.
increase in women in just 21 years. 8 Furthermore, there is a new interest in neurological diseases in Latin America and Asia, with a rising incidence than previously, although the rates remain lower than those found in developed countries, 2, 12, 13 suggesting this is increasingly a worldwide phenomenon.
The rises in neurological mortality have been questioned as an artefact, for example, due to improved diagnosis of ALS 14 and the effect of changing demographics giving rise to the "Gompertzian hypothesis." This states that the neurological increases are a consequence of people living longer and therefore developing age-related diseases that they had not lived long enough to develop previously. [15] [16] [17] However, the diagnostic issue has limited impact as it is mortality rates that are measured not separate diagnostic categories, and at this point, there is little evidence of diagnostic uncertainty as the primary cause of death is categorized as being due to a neurological condition. 1, [5] [6] [7] [8] Moreover, the Gompertzian position appears to have ignored the marked changes between the sexes and in different countries. 1, [5] [6] [7] [8] [9] [10] [11] Crucially, the Gompertzian hypothesis does not account for the substantial rise in early onset dementia reported in many Western countries. 12, 13, [18] [19] [20] [21] [22] To reduce a primarily Gompertzian explanation, this populationbased study focuses upon people aged 55-74 years, below life expectancies in the developed world and utilizes the latest WHO data, updated December 2016 to take the analysis up to 2014. 23 Consequently, studying the adults aged 55-74 over a relatively short time means any Gompertzian influence will be minimal. However, to place the results on adults aged 55-74 in a wider context, the over-75s rates and matching population increases are also examined to explore any possible strengths of the Gompertzian influence.
Two control mortalities are juxtaposed against neurological death rates, Cancer Mortality and Circulatory Disease Deaths (CDD) because they are considered age related. It should be noted, however, that this analysis is not designed to postulate about possible aetiologies, but only to determine whether there continues to be substantial increases in neurological deaths over the past two decades and whether there are any significant differences in the US rates and the other nations.
There are four working null hypotheses; in each country between 1989-91 and 2012-14 that there will be no statistically significant differences between:
Total Neurological Deaths and Cancer Mortality;
2. Total Neurological Deaths and CDD, 3. between USA neurological death rates and the other twenty developed countries, and 4. no statistical association between rises in neurological deaths and falls in the control mortalities of Cancer and CDD.
| Statistics
Confidence intervals (to ±95% significance) are used to compare changes between the control mortalities and TND over the period and between the USA and the other countries. Spearman's rank order correlation examines any link between increases in neurological mortality any decreases in either Cancer or CDD deaths. Odds ratio calculates proportional differences between ratios of change, from which a ratio of ratios is calculated. An example best explains this. Rises in neurological deaths 5, 7, 8 had been attributed to rises in population [15] [16] [17] . Odds ratio tests this using the ratio of change in the USA elderly population, 1989 and 2014, giving a ratio of 1.49 and divides it into the ratio of change of neurological deaths, 5.13 and the ensuing ratio of ratios is the odds ratio of 3.44. Neurological deaths rose by >10% in eleven countries-Portugal 72% Greece 65%, Denmark and Finland 63%, the USA 43%, Spain 39%, Japan 32%, Germany 28%, Sweden 18%, Norway 15% and Australia, 13%. There were falls >5 in Belgium, Canada, France and New Zealand. In the earlier 1989-91 period, the USA was the 10th highest of the twenty-one countries but is now second highest.
| RESULTS

| Male (55-74) TND
| Female (55-74) TND
The highest rates were Finland 924 pm, USA 618 pm and the UK 564 pm, the lowest being Japan 176 pm, Greece 252 pm and Austria 334 pm.
Ten countries female rates rose by more than >10% in Portugal 96%, the USA 68%, Greece and Finland 53%, Netherlands 38%, Denmark 35%, Spain 12%, Australia 17%, Germany 16% and Ireland 14%. There were falls in Belgium of 16%, France 6% and Canada 4%.
At the base-line years, USA female rates were 11th highest but are now second.
Male and female current rates were significantly correlated (Rho=+0.7714, P<.001).
Over the period, there were only few changes between the gender, male and female 1989-91 rates correlated (Rho=+0.8263) and in 2012-14 (Rho=+0.8429, P<.001). Table 2 lists over-75s rates of both sexes and population increases. The highest was Finland at 20 562 pm followed by the rises than twelve other countries, and no country had bigger increases than the USA.
| Over-75s TND as context 1989-2014
| USA v other countries
USA female rates rose significantly more than seventeen other countries, whilst no other country had bigger increases than the USA. There was a significant negative correlation between decreases in cancer mortality with increases in neurological death (Rho=−0.4521, P<.025).
| Control mortalities
| Males: Cancer
| Male CDD
The initial Western average rate was 9118 pm falling to 3321 pm, an equivalent fall of 64%. The highest CDD was Finland 5056 pm, the lowest France 2354 pm, the USA was third highest at 4509 pm but equivalent to a fall of 58%.
There was a slight none significant negative correlation between decreases in CDD and rises in neurological deaths (Rho=−0.2050 n.sig). There was no significant correlation between decreases in female cancer and increases in neurological deaths (Rho=−0.1312 n.sig).
| Females: Cancer
| Female CDD
The Western average was 1432 pm, representing a fall of 67% over the period, the highest was the USA 3879 pm, although equivalent to a 46% reduction over the period, the lowest was France 852 pm.
There was no significant correlation between decreases in CDD and rises in neurological deaths (Rho=−0.2618 n.sig). This pattern was found for Female cancer and CDD neurological seventeen and nineteen countries, respectively.
| Comparing control to neurological deaths
| Rates are statistics-numbers people
Mortality rates are "statistics," whereas actual numbers of people can give a better feel to the practice reality of these increases.
In 1979, there were 28 261 American TND deaths of which 11 033 were in the 55-74 age band. By 1989, these had risen to 
| CONCLUSIONS
| Limitations to the study
Death rates depend upon the reliability of diagnosis, which some believe have resulted in higher specific diagnosis of ALS. 14 However, as the measures are in the broad category of neurological diseases, this is less of a problem [1.5-8] . The claims that increases in neurological morbidity are due to the Gompertzian effect [15] [16] [17] is largely questionable, as the 55-74 age band is below current Western life expectancy. 23 Moreover, the fourfold rise in the American over-75s TND rates, emerged from just a 49% increase of the elderly population counters a primarily Gompertzian explanation.
Finally, aggregated international studies cannot account for any particular country's substantial changes, which will require countryspecific research possibly requiring a geo-epidemiology approach which involves detailed mapping of cases right down to houses in street locations. 24
| Main findings
We can reject all four null hypotheses as neurological deaths rose significantly more than the control deaths in every country and for both sexes. Furthermore, whilst no other country had greater rises in their neurological deaths than the USA, American male and female neurological deaths rose significantly more than twelve and seventeen countries, respectively, occurring only just 25 years. Furthermore, there was no positive statistical link between increases in neurological The values for USA are highlighted in bold.
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deaths and decreases in the control mortalities, which would have been expected if the Gompertzian was a strong factor. Moreover, compared with the earlier analyses between 1989 and 2010 where there were notable rises in males in six countries and in four countries for females, by 2014 there had been rises of equivalent to >10% in twelve countries for men and in eleven countries for females. A Gompertzian perspective also ignores rises in early onset dementia (EOD) reported in many countries. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 19, 20, 22, 25 For example, one found 29% of their cohort were aged under 65 years, which 30 years before would have been considered extraordinary. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 19, 20, 22, 25 Another indication of the extent of increased EOD is seen in examining Medline studies related to EOD. The first paper was published June 1967 by June 1987 there were 100 papers, whereas from January to December 2016, there were 299 directly or indirectly related to EOD, clearly whatever the multiple causal explanations, something has changed.
Moreover, the over-75's TND results showed that the increases were essentially far in excess of rises in the over-75's population.
Whilst there may be some Gompertzian influences related to demography it does not appear to be the predominant factor, especially in the USA and nine other countries whose elderly population to TND rates produced odds ratios that had more than doubled.
The study adds confirmation that the changes noted at the end of the last century, are continuing, and despite the limitations, provides valid data for future research, whilst raising questions as to what might account for these global changes.
Although this study does not attempt to explain the reasons behind these increases, it is clear that the neurological morbidity is starting earlier and the reported rises are not primarily an artefact. There are confirmed rises of ALS from a number of Western clinical studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 25 as well as small increases in Asian and Latin American countries. 18, 19 This is not to discount studies that identified genetic and familial patterns 20-22 but others recognize lifestyle and possible interactive environmental contributions. 2, 4, [6] [7] [8] 25 Including such factors as occupation, heavy metals, petro-chemicals, organophosphate/pesticides [26] [27] [28] [29] [30] and possible influence of electromagnetic field (EMF) 18, 25, 31 and military service. 32 Although not all studies related to ALS have consistently reported environmental factors, 33 the majority have highlighted environmental factors rather than longevity [4] [5] [6] [7] [8] 18, [25] [26] [27] [28] [29] [30] as well as epigenetic changes, [33] [34] [35] whist recently, research had linked rises in dementias to proximity to major roads. 30 This project is not equipped to explain the reasons behind these changes, but in view of the relatively short period, it is indicative that At a practice level, both families and the medical specialities dealing with the concomitant problems of neurological disease are in danger of being overwhelmed. In particular, is issue of relatively younger neurological patients burden upon their families, complicated by the psychiatric and psychosocial problems associated with neurological disease. Moreover, until the extent of these changes is recognized the present configuration of services will be overwhelmed. Consequently, there is an urgent need for cross-disciplinary research to understand the underlying interactive processes that contribute to rises in neurological morbidity and mortality and for the necessary communitybased support that will be needed until or if effective preventative and/or treatments can be introduced.
